Niagen Bioscience, Inc.
NAGE- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001386570
No open-market purchases or sales by Niagen Bioscience, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $102.1M in total; no superinvestor holds it.
Holders of 5% or more of NAGE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Niagen Bioscience, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G | 5.20%4.16M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Niagen Bioscience, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.20%4.16M shares | New | Jun 30, 2026 | SEC |
| Jan 30, 20262:16 PM ET | Vanguard Group Inc | 13G/A | 4.11%3.29M shares | −0.93 ppfrom 5.04%Below 5% | Dec 31, 2025 | SEC |
| Oct 31, 202511:03 AM ET | Vanguard Group Inc | 13G | 5.04%4.02M shares | New | Sep 30, 2025 | SEC |
| Oct 19, 2022 | Societe des Produits Nestle S.A. | 13GOld format | – | New | – | SEC |
| Oct 3, 2022 | Champion River Ventures Ltd | 13D/AOld format | – | – | – | SEC |
| Oct 3, 2022 | Pioneer Step Holdings Ltd | 13D/AOld format | – | – | – | SEC |
| Jun 27, 2022 | Yong Rong (HK) Asset Management Ltd | 13G/AOld format | – | – | – | SEC |
| May 20, 2022 | Shing Li Ka | 13D/AOld format | – | – | – | SEC |
| May 20, 2022 | Pioneer Step Holdings Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Yong Rong (HK) Asset Management Ltd | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Li Ka Shing (Global) Foundation | 13G/AOld format | – | – | – | SEC |
| Sep 21, 2021 | Chau Hoi Shuen Solina Holly | 13D/AOld format | – | – | – | SEC |
| Sep 20, 2021 | Chau Hoi Shuen Solina Holly | 13D/AOld format | – | – | – | SEC |
| Sep 17, 2021 | Chau Hoi Shuen Solina Holly | 13D/AOld format | – | – | – | SEC |
| Apr 9, 2021 | Yong Rong (HK) Asset Management Ltd | 13G/AOld format | – | – | – | SEC |
| Mar 25, 2021 | Yong Rong (HK) Asset Management Ltd | 13G/AOld format | – | – | – | SEC |
| Mar 2, 2021 | Frost Phillip MD Et Al | 13D/AOld format | – | – | – | SEC |
| Feb 26, 2021 | Yong Rong (HK) Asset Management Ltd | 13GOld format | – | New | – | SEC |
| Feb 9, 2021 | Li Ka Shing (Global) Foundation | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Niagen Bioscience, Inc. shares.
No Form 144 notices for Niagen Bioscience, Inc. are on file.